SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.
Príomhchruthaitheoir: | Meem, Manila |
---|---|
Rannpháirtithe: | Akter, Dr. Raushanara |
Formáid: | Tráchtas |
Teanga: | English |
Foilsithe / Cruthaithe: |
Brac University
2023
|
Ábhair: | |
Rochtain ar líne: | http://hdl.handle.net/10361/18081 |
Míreanna comhchosúla
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
de réir: Islam, Saidul
Foilsithe / Cruthaithe: (2022) -
RIPK pathway, as a potential target, for cancer treatment - a review
de réir: Jahan, Nusrat
Foilsithe / Cruthaithe: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
de réir: Flora, Sanzida Alam
Foilsithe / Cruthaithe: (2024) -
Immunotherapy in the Management of Lung Cancer
de réir: Tasnim, Humayra
Foilsithe / Cruthaithe: (2022) -
A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
de réir: Ratu, Tabassum
Foilsithe / Cruthaithe: (2024)